TABLE 5.
Adjusted ORs and 95% CIs for Early Discontinuation in Medicaid-Covered Patients (n = 7,931)
| Covariates | Adjusted OR | 95% CI |
|---|---|---|
| Drug regimen | ||
| OPrD | Reference | – |
| SIM/SOF | 0.80 | 0.38-1.71 |
| LDV/SOF | 0.26 | 0.18-0.39 |
| SOF/VEL | 0.22 | 0.13-0.38 |
| EBR/GZR | 0.24 | 0.15-0.40 |
| GLE/PIB | 0.07 | 0.02-0.28 |
| Use of ribavirin during follow-up | 0.93 | 0.66-1.33 |
| Age (5-year increments) | 0.91 | 0.86-0.96 |
| Sex (female vs. male) | 1.15 | 0.94-1.42 |
| Year of cohort entry | ||
| 2014 | Reference | – |
| 2015 | 1.34 | 0.70-2.59 |
| 2016 | 1.01 | 0.52-1.97 |
| 2017 | 1.42 | 0.72-2.82 |
| Race (black vs. nonblack) | 1.04 | 0.83-1.30 |
| Cirrhosis | 1.13 | 0.87-1.46 |
| Anemia | 1.07 | 0.76-1.49 |
| Diabetes | 1.26 | 0.97-1.64 |
| HIV infection | 1.33 | 0.73-2.43 |
| Charlson Comorbidity Index | 0.98 | 0.92-1.04 |
| Drug abuse | 1.02 | 0.76-1.37 |
| Alcohol abuse | 1.36 | 1.02-1.82 |
| Number of physician visits | 1.00 | 0.99-1.01 |
| Number of ED visits | 1.01 | 0.99-1.04 |
| Number of hospitalizations | 1.01 | 0.91-1.12 |
CI = confidence interval; EBR/GZR = elbasvir/grazoprevir; ED = emergency department; GLE/PIB = glecaprevir/pibrentasvir; HIV = human immunodeficiency virus; LDV/SOF = ledipasvir/sofosbuvir; OPrD = ombitasvir/paritaprevir/ritonavir + dasabuvir; OR = odds ratio; SIM/SOF = simeprevir/sofosbuvir; SOF/VEL = sofosbuvir/velpatasvir.